OncoMatch/Clinical Trials/NCT04254419
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Is NCT04254419 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NK cells for high grade glioma.
Treatment: NK cells — Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week. TGFβi NK cell infusions should be delivered at least 3 days apart (e.g., Friday of Week 1 and Monday of Week 2). Dose will be escalated in an inter-patient stepwise fashion consisting of 3 dose levels.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Grade: high grade
recurrent, progressive, or refractory malignant CNS tumor
Lab requirements
Blood counts
Adequate bone marrow function, without transfusion or growth factors within 21 days of NK cell administration.
Kidney function
Adequate Renal Function
Liver function
Adequate liver function
Adequate bone marrow function, without transfusion or growth factors within 21 days of NK cell administration. Adequate liver function. Adequate Renal Function. Prothrombin time/international normalized ratio. Adequate neurologic function defined.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nationwide Children's Hospital · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify